List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim Intertiol GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer